Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein e level in alzheimer's disease patients

Molecular and Cellular Proteomics

Volumn 13, Issue 2, 2014, Pages 407-419

  Han, Sun Ho ^a   Kim, Jun Seok ^b   Lee, Youngju ^b   Choi, Heesun ^a   Kim, Jong Won ^c   Na, Duk Lyul ^c   Yang, Eun Gyeong ^b   Yu, Myeong Hee ^b   Hwang, Daehee ^d   Lee, Cheolju ^b   Mook Jung, Inhee ^a  

^a Seoul National University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CHEMICAL MODIFICATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; LIQUID CHROMATOGRAPHY SELECTED REACTION MONITORING MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; APOLIPOPROTEINS E; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MASS SPECTROMETRY; MICROSPHERES; MIDDLE AGED; MOLECULAR SEQUENCE DATA; REPRODUCIBILITY OF RESULTS;

EID: 84893208400     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M113.028639     Document Type: Article

References (65)

1. Hardy, J. A., and Higgins, G. A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185
2. Hardy, J., and Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 12, 383-388
3. Hardy, J., and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356
4. Alloul, K., Sauriol, L., Kennedy, W., Laurier, C., Tessier, G., Novosel, S., and Contandriopoulos, A. (1998) Alzheimer's disease: a review of the disease, its epidemiology and economic impact. Arch. Gerontol. Geriatr. 27, 189-221
5. Wimo, A., Winblad, B., and Grafstrom, M. (1999) The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment. Int. J. Geriatr. Psychiatry 14, 338-347
6. Buckholtz, N. S. (2011) Perspective: in search of biomarkers. Nature 475, S8
7. Callaway, E. (2012) Alzheimer's drugs take a new tack. Nature 489, 13-14
8. Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R., Dartigues, J. F., Kragh-Sorensen, P., Lobo, A., Martinez-Lage, J. M., Stijnen, T., and Hofman, A. (1999) Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 52, 78-84
9. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak- Vance, M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923
10. Tsai, M. S., Tangalos, E. G., Petersen, R. C., Smith, G. E., Schaid, D. J., Kokmen, E., Ivnik, R. J., and Thibodeau, S. N. (1994) Apolipoprotein E: risk factor for Alzheimer disease. Am. J. Hum. Genet. 54, 643-649
11. Roses, A. D. (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387-400
12. Siest, G., Pillot, T., Regis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., and Visvikis, S. (1995) Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin. Chem. 41, 1068-1086
13. Mahley, R. W., and Rall, S. C., Jr. (2000) Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1, 507-537
14. Eichner, J. E., Dunn, S. T., Perveen, G., Thompson, D. M., Stewart, K. E., and Stroehla, B. C. (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155, 487-495
15. Martins, R. N., Clarnette, R., Fisher, C., Broe, G. A., Brooks, W. S., Montgomery, P., and Gandy, S. E. (1995) ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. Neuroreport 6, 1513-1516
16. Ueki, A., Kawano, M., Namba, Y., Kawakami, M., and Ikeda, K. (1993) A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease. Neurosci. Lett. 163, 166-168
17. Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper- MacLachlan, D. R., Alberts, M. J., Hulette, C., Crain, B., Goldgaber, D., and Roses, A. D. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472
18. Higgins, G. A., Large, C. H., Rupniak, H. T., and Barnes, J. C. (1997) Apolipoprotein E and Alzheimer's disease: a review of recent studies. Pharmacol. Biochem. Behav. 56, 675-685
19. Kim, H. C., Kim, D. K., Choi, I. J., Kang, K. H., Yi, S. D., Park, J., and Park, Y. N. (2001) Relation of apolipoprotein E polymorphism to clinically diagnosed Alzheimer's disease in the Korean population. Psychiatry Clin. Neurosci. 55, 115-120
20. Martins, I. J., Hone, E., Foster, J. K., Sunram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., and Martins, R. N. (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol. Psychiatry 11, 721-736
21. Taddei, K., Clarnette, R., Gandy, S. E., and Martins, R. N. (1997) Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci. Lett. 223, 29-32
22. Slooter, A. J., de Knijff, P., Hofman, A., Cruts, M., Breteler, M. M., Van Broeckhoven, C., Havekes, L. M., and van Duijn, C. M. (1998) Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci. Lett. 248, 21-24
23. Siest, G., Bertrand, P., Qin, B., Herbeth, B., Serot, J. M., Masana, L., Ribalta, J., Passmore, A. P., Evans, A., Ferrari, M., Franceschi, M., Shepherd, J., Cuchel, M., Beisiegel, U., Zuchowsky, K., Rukavina, A. S., Sertic, J., Stojanov, M., Kostic, V., Mitrevski, A., Petrova, V., Sass, C., Merched, A., Salonen, J. T., Tiret, L., and Visvikis, S. (2000) Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin. Chem. Lab. Med. 38, 721-730
24. Panza, F., Solfrizzi, V., Colacicco, A. M., Basile, A. M., D'Introno, A., Capurso, C., Sabba, M., Capurso, S., and Capurso, A. (2003) Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. Neuroreport 14, 605-608
25. Vincent-Viry, M., Schiele, F., Gueguen, R., Bohnet, K., Visvikis, S., and Siest, G. (1998) Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. Clin. Chem. 44, 957-965
26. Mui, S., Briggs, M., Chung, H., Wallace, R. B., Gomez-Isla, T., Rebeck, G. W., and Hyman, B. T. (1996) A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele
27. Artiga, M. J., Bullido, M. J., Sastre, I., Recuero, M., Garcia, M. A., Aldudo, J., Vazquez, J., and Valdivieso, F. (1998) Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 421, 105-108
28. Lambert, J. C., Pasquier, F., Cottel, D., Frigard, B., Amouyel, P., and Chartier-Harlin, M. C. (1998) A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum. Mol. Genet. 7, 533-540
29. Kuzyk, M. A., Smith, D., Yang, J. C., Cross, T. J., Jackson, A. M., Hardie, D. B., Anderson, N. L., and Borchers, C. H. (2009) Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 8, 1860-1877
30. Whiteaker, J. R., Lin, C., Kennedy, J., Hou, L., Trute, M., Sokal, I., Yan, P., Schoenherr, R. M., Zhao, L., Voytovich, U. J., Kelly-Spratt, K. S., Krasnoselsky, A., Gafken, P. R., Hogan, J. M., Jones, L. A., Wang, P., Amon, L., Chodosh, L. A., Nelson, P. S., McIntosh, M. W., Kemp, C. J., and Paulovich, A. G. (2011) A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 29, 625-634
31. Jaffe, J. D., Keshishian, H., Chang, B., Addona, T. A., Gillette, M. A., and Carr, S. A. (2008) Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol. Cell. Proteomics 7, 1952-1962
32. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C., Lacoux, X., Morla, A., Choquet-Kastylevsky, G., and Lemoine, J. (2009) Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell. Proteomics 8, 1006-1015
33. Picotti, P., Rinner, O., Stallmach, R., Dautel, F., Farrah, T., Domon, B., Wenschuh, H., and Aebersold, R. (2010) High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 7, 43-46
34. Mirzaei, H., McBee, J. K., Watts, J., and Aebersold, R. (2008) Comparative evaluation of current peptide production platforms used in absolute quantification in proteomics. Mol. Cell. Proteomics 7, 813-823
35. Sherwood, C. A., Eastham, A., Lee, L. W., Risler, J., Vitek, O., and Martin, D. B. (2009) Correlation between y-type ions observed in ion trap and triple quadrupole mass spectrometers. J. Proteome Res. 8, 4243-4251
36. Olsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., and Blennow, K. (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336-345
37. Gordon, R. F., and McDade, R. L. (1997) Multiplexed quantification of human IgG, IgA, and IgM with the FlowMetrix system. Clin. Chem. 43, 1799-1801
38. Oliver, K. G., Kettman, J. R., and Fulton, R. J. (1998) Multiplexed analysis of human cytokines by use of the FlowMetrix system. Clin. Chem. 44, 2057-2060
39. Prabhakar, U., Eirikis, E., and Davis, H. M. (2002) Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J. Immunol. Methods 260, 207-218
40. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
41. Simon, R., Girod, M., Fonbonne, C., Salvador, A., Clement, Y., Lanteri, P., Amouyel, P., Lambert, J. C., and Lemoine, J. (2012) Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case control study by targeted mass spectrometry (n-669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics 11, 1389-1403
42. Anderson, L., and Hunter, C. L. (2006) Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5, 573-588
43. Proc, J. L., Kuzyk, M. A., Hardie, D. B., Yang, J., Smith, D. S., Jackson, A. M., Parker, C. E., and Borchers, C. H. (2010) A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J. Proteome Res. 9, 5422-5437
44. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198
45. Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., and Laughlin, M. A. (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7, 483-493
46. Hendrie, H. C., Ogunniyi, A., Hall, K. S., Baiyewu, O., Unverzagt, F. W., Gureje, O., Gao, S., Evans, R. M., Ogunseyinde, A. O., Adeyinka, A. O., Musick, B., and Hui, S. L. (2001) Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 285, 739-747
47. Osuntokun, B. O., Sahota, A., Ogunniyi, A. O., Gureje, O., Baiyewu, O., Adeyinka, A., Oluwole, S. O., Komolafe, O., Hall, K. S., Unverzagt, F. W., Hui, S. L., Yang, M. S., and Hendric, H. C. (1995) Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. Ann. Neurol. 38, 463-465
48. Brown, J. A., Terashima, K. H., Burggren, A. C., Ercoli, L. M., Miller, K. J., Small, G. W., and Bookheimer, S. Y. (2011) Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proc. Natl. Acad. Sci. U.S.A. 108, 20760-20765
49. Lehtimaki, T., Pirttila, T., Mehta, P. D., Wisniewski, H. M., Frey, H., and Nikkari, T. (1995) Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum. Genet. 95, 39-42
50. Scacchi, R., Gambina, G., Ruggeri, M., Martini, M. C., Ferrari, G., Silvestri, M., Schiavon, R., and Corbo, R. M. (1999) Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci. Lett. 259, 33-36
51. Sing, C. F., and Davignon, J. (1985) Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37, 268-285
52. Berglund, L., Wiklund, O., Eggertsen, G., Olofsson, S. O., Eriksson, M., Linden, T., Bondjers, G., and Angelin, B. (1993) Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy. J. Intern. Med. 233, 173-178
53. Fukumoto, H., Ingelsson, M., Garevik, N., Wahlund, L. O., Nukina, N., Yaguchi, Y., Shibata, M., Hyman, B. T., Rebeck, G. W., and Irizarry, M. C. (2003) APOE epsilon 3/epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp. Neurol. 183, 249-253
54. Gupta, V. B., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., Lui, J. K., Masters, C., Rowe, C. C., Szoeke, C., Taddei, K., and Martins, R. N. (2011) Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76, 1091-1098
55. Hallman, D. M., Boerwinkle, E., Saha, N., Sandholzer, C., Menzel, H. J., Csazar, A., and Utermann, G. (1991) The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am. J. Hum. Genet. 49, 338-349
56. Haddy, N., De Bacquer, D., Chemaly, M. M., Maurice, M., Ehnholm, C., Evans, A., Sans, S., Do Carmo Martins, M., De Backer, G., Siest, G., and Visvikis, S. (2002) The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. Eur. J. Hum. Genet. 10, 841-850
57. Schiele, F., De Bacquer, D., Vincent-Viry, M., Beisiegel, U., Ehnholm, C., Evans, A., Kafatos, A., Martins, M. C., Sans, S., Sass, C., Visvikis, S., De Backer, G., and Siest, G. (2000) Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 152, 475-488
58. Hong, Y. J., Yoon, B., Shim, Y. S., Cho, A. H., Shin, H. E., Kim, Y. I., Kim, S. Y., and Yang, D. W. (2011) APOE epsilon4 allele status in Korean dementia patients with severe white matter hyperintensities. J. Alzheimers Dis. 24, 519-524
59. Juva, K., Sulkava, R., Erkinjuntti, T., Ylikoski, R., Valvanne, J., and Tilvis, R. (1994) Staging the severity of dementia: comparison of clinical (CDR, DSM-III-R), functional (ADL, IADL) and cognitive (MMSE) scales. Acta Neurol. Scand. 90, 293-298
60. Perneczky, R., Wagenpfeil, S., Komossa, K., Grimmer, T., Diehl, J., and Kurz, A. (2006) Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am. J. Geriatr. Psychiatry 14, 139-144
61. Brun, V., Dupuis, A., Adrait, A., Marcellin, M., Thomas, D., Court, M., Vandenesch, F., and Garin, J. (2007) Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol. Cell. Proteomics 6, 2139-2149
62. Pan, S., Chen, R., Brand, R. E., Hawley, S., Tamura, Y., Gafken, P. R., Milless, B. P., Goodlett, D. R., Rush, J., and Brentnall, T. A. (2012) Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J. Proteome Res. 11, 1937-1948
63. Huttenhain, R., Malmstrom, J., Picotti, P., and Aebersold, R. (2009) Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 13, 518-525
64. Simon, R., Girod, M., Fonbonne, C., Salvador, A., Clement, Y., Lanteri, P., Amouyel, P., Lambert, J. C., and Lemoine, J. (2012) Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n -669): a pilot assay for methioninecontaining proteotypic peptides. Mol. Cell. Proteomics 11, 1389-1403
65. Doraiswamy, P. M., Bieber, F., Kaiser, L., Krishnan, K. R., Reuning-Scherer, J., and Gulanski, B. (1997) The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 48, 1511-1517